Guido Grandi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2262263/publications.pdf

Version: 2024-02-01

69 papers	11,857 citations	81900 39 h-index	102487 66 g-index

72 all docs	72 docs citations	72 times ranked	11046 citing authors

#	Article	IF	Citations
1	Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: Implications for the microbial "pan-genome". Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13950-13955.	7.1	2,161
2	Binding of Hepatitis C Virus to CD81. Science, 1998, 282, 938-941.	12.6	1,814
3	Identification of Vaccine Candidates Against Serogroup B Meningococcus by Whole-Genome Sequencing. Science, 2000, 287, 1816-1820.	12.6	1,258
4	Complete Genome Sequence of Neisseria meningitidis Serogroup B Strain MC58. Science, 2000, 287, 1809-1815.	12.6	1,083
5	Identification of a Universal Group B Streptococcus Vaccine by Multiple Genome Screen. Science, 2005, 309, 148-150.	12.6	497
6	Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype VStreptococcus agalactiae. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 12391-12396.	7.1	447
7	Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nature Biotechnology, 2006, 24, 191-197.	17.5	407
8	Group A Streptococcus produce pilus-like structures containing protective antigens and Lancefield T antigens. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 15641-15646.	7.1	329
9	Genome Analysis Reveals Pili in Group B Streptococcus. Science, 2005, 309, 105-105.	12.6	278
10	Group B Streptococcus: global incidence and vaccine development. Nature Reviews Microbiology, 2006, 4, 932-942.	28.6	272
11	Genomic Approach for Analysis of Surface Proteins inChlamydia pneumoniae. Infection and Immunity, 2002, 70, 368-379.	2.2	209
12	Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nature Biotechnology, 2002, 20, 914-921.	17.5	205
13	Preventing Bacterial Infections with Pilus-Based Vaccines: the Group B Streptococcus Paradigm. Journal of Infectious Diseases, 2009, 199, 108-115.	4.0	201
14	Identification of novel genomic islands coding for antigenic pilus-like structures inStreptococcus agalactiae. Molecular Microbiology, 2006, 61, 126-141.	2.5	190
15	Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 3680-3685.	7.1	166
16	Outer membrane vesicles from groupâ€…BNeisseria meningitidis Î”gna33 mutant: Proteomic and immunological comparison with detergent-derived outer membrane vesicles. Proteomics, 2006, 6, 1856-1866.	2.2	151
17	Proteomics Characterization of Outer Membrane Vesicles from the Extraintestinal Pathogenic Escherichia coli Î”tolR IHE3034 Mutant. Molecular and Cellular Proteomics, 2008, 7, 473-485.	3.8	115
18	Multi High-Throughput Approach for Highly Selective Identification of Vaccine Candidates: the Group A Streptococcus Case. Molecular and Cellular Proteomics, 2012, 11, M111.015693.	3.8	115

#	Article	IF	Citations
19	Antibacterial vaccine design using genomics and proteomics. Trends in Biotechnology, 2001, 19, 181-188.	9.3	106
20	Antibodyâ€mediated immunity induced by engineered Escherichia coli OMVs carrying heterologous antigens in their lumen. Journal of Extracellular Vesicles, 2014, 3, .	12.2	97
21	Surfome Analysis as a Fast Track to Vaccine Discovery. Molecular and Cellular Proteomics, 2009, 8, 1728-1737.	3.8	90
22	CsrRS Regulates Group BStreptococcusVirulence Gene Expression in Response to Environmental pH: a New Perspective on Vaccine Development. Journal of Bacteriology, 2009, 191, 5387-5397.	2.2	88
23	BibA: a novel immunogenic bacterial adhesin contributing to group B Streptococcus survival in human blood. Molecular Microbiology, 2007, 63, 754-67.	2.5	87
24	Recombinant outer membrane vesicles carrying Chlamydia muridarum HtrA induce antibodies that neutralize chlamydial infection in vitro. Journal of Extracellular Vesicles, 2013, 2, .	12.2	86
25	Approach to discover T- and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 9969-9974.	7.1	80
26	Mg²⁺ signalling defines the group A streptococcal CsrRS (CovRS) regulon. Molecular Microbiology, 2007, 65, 671-683.	2.5	71
27	Evaluation of Hepatitis C Virus Glycoprotein E2 for Vaccine Design: an Endoplasmic Reticulum-Retained Recombinant Protein Is Superior to Secreted Recombinant Protein and DNA-Based Vaccine Candidates. Journal of Virology, 2000, 74, 6885-6892.	3.4	70
28	Analysis of Two-Component Systems in Group B Streptococcus Shows That RgfAC and the Novel FspSR Modulate Virulence and Bacterial Fitness. MBio, 2014, 5, e00870-14.	4.1	67
29	Bacterial outer membrane vesicles engineered with lipidated antigens as a platform for Staphylococcus aureus vaccine. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 21780-21788.	7.1	66
30	Large scale validation of an efficient CRISPR/Cas-based multi gene editing protocol in Escherichia coli. Microbial Cell Factories, 2017, 16, 68.	4.0	64
31	Pilus Backbone Contributes to Group BStreptococcusParacellular Translocation through Epithelial Cells. Journal of Infectious Diseases, 2008, 198, 890-898.	4.0	58
32	Angiopoietin-like 7, a novel pro-angiogenetic factor over-expressed in cancer. Angiogenesis, 2014, 17, 881-896.	7.2	55
33	Whole-genome epidemiology, characterisation, and phylogenetic reconstruction of Staphylococcus aureus strains in a paediatric hospital. Genome Medicine, 2018, 10, 82.	8.2	54
34	The Protective Value of Maternal Group BStreptococcusAntibodies: Quantitative and Functional Analysis of Naturally Acquired Responses to Capsular Polysaccharides and Pilus Proteins in European Maternal Sera. Clinical Infectious Diseases, 2016, 63, 746-753.	5.8	53
35	GNA33 of Neisseria meningitidis Is a Lipoprotein Required for Cell Separation, Membrane Architecture, and Virulence. Infection and Immunity, 2004, 72, 1914-1919.	2.2	51
36	Synergistic Protective Activity of Tumor-Specific Epitopes Engineered in Bacterial Outer Membrane Vesicles. Frontiers in Oncology, 2017, 7, 253.	2.8	50

#	Article	IF	Citations
37	Environmental Acidification Drives S. pyogenes Pilus Expression and Microcolony Formation on Epithelial Cells in a FCT-Dependent Manner. PLoS ONE, 2010, 5, e13864.	2.5	47
38	Streptococcus agalactiae Capsule Polymer Length and Attachment Is Determined by the Proteins CpsABCD. Journal of Biological Chemistry, 2015, 290, 9521-9532.	3.4	45
39	Identification of new potential vaccine candidates against Chlamydia pneumoniae by multiple screenings. Vaccine, 2005, 23, 1178-1188.	3.8	44
40	BibA Induces Opsonizing Antibodies Conferring In Vivo Protection against Group BStreptococcus. Journal of Infectious Diseases, 2009, 200, 564-570.	4.0	41
41	Bacterial surface proteins and vaccines. F1000 Biology Reports, 2010, 2, .	4.0	41
42	GNA33 fromNeisseria meningitidisserogroup B encodes a membrane-bound lytic transglycosylase (MltA). FEBS Journal, 2002, 269, 3722-3731.	0.2	37
43	Coordinate Transcription and Physical Linkage of Domains in Surfactin Synthetase Are Not Essential for Proper Assembly and Activity of the Multienzyme Complex. Journal of Biological Chemistry, 1998, 273, 14403-14410.	3.4	30
44	Some Gram-negative Lipoproteins Keep Their Surface Topology When Transplanted from One Species to Another and Deliver Foreign Polypeptides to the Bacterial Surface. Molecular and Cellular Proteomics, 2017, 16, 1348-1364.	3.8	29
45	Protectome Analysis: A New Selective Bioinformatics Tool for Bacterial Vaccine Candidate Discovery. Molecular and Cellular Proteomics, 2015, 14, 418-429.	3.8	25
46	FAT1: a potential target for monoclonal antibody therapy in colon cancer. British Journal of Cancer, 2016, 115, 40-51.	6.4	25
47	Proteomeâ€minimized outer membrane vesicles from Escherichia coli as a generalized vaccine platform. Journal of Extracellular Vesicles, 2021, 10, e12066.	12.2	24
48	Genomics and Proteomics in Reverse Vaccines. Methods of Biochemical Analysis, 2005, 49, 379-393.	0.2	22
49	A new flow-cytometry-based opsonophagocytosis assay for the rapid measurement of functional antibody levels against Group B Streptococcus. Journal of Immunological Methods, 2012, 378, 11-19.	1.4	22
50	Functional activity of maternal and cord antibodies elicited by an investigational group B Streptococcus trivalent glycoconjugate vaccine in pregnant women. Journal of Infection, 2018, 76, 449-456.	3.3	22
51	A new human growth hormone production process using a recombinant Bacillus subtilis strain. Journal of Biotechnology, 1991, 18, 41-54.	3.8	20
52	SpyAD, a Moonlighting Protein of Group A Streptococcus Contributing to Bacterial Division and Host Cell Adhesion. Infection and Immunity, 2014, 82, 2890-2901.	2.2	20
53	ERMP1, a novel potential oncogene involved in UPR and oxidative stress defense, is highly expressed in human cancer. Oncotarget, 2016, 7, 63596-63610.	1.8	20
54	Structure, dynamics and immunogenicity of a catalytically inactive CXC chemokine-degrading protease SpyCEP from Streptococcus pyogenes. Computational and Structural Biotechnology Journal, 2020, 18, 650-660.	4.1	19

#	Article	IF	Citations
55	Protective effect of Group B Streptococcus type-III polysaccharide conjugates against maternal colonization, ascending infection and neonatal transmission in rodent models. Scientific Reports, 2018, 8, 2593.	3.3	18
56	Vaccination With a FAT1-Derived B Cell Epitope Combined With Tumor-Specific B and T Cell Epitopes Elicits Additive Protection in Cancer Mouse Models. Frontiers in Oncology, 2018, 8, 481.	2.8	18
57	Auto-Assembling Detoxified Staphylococcus aureus Alpha-Hemolysin Mimicking the Wild-Type Cytolytic Toxin. Vaccine Journal, 2016, 23, 442-450.	3.1	17
58	Multi-Antigen Outer Membrane Vesicle Engineering to Develop Polyvalent Vaccines: The Staphylococcus aureus Case. Frontiers in Immunology, 2021, 12, 752168.	4.8	12
59	A novel polyclonal antibody library for expression profiling of poorly characterized, membrane and secreted human proteins. Journal of Proteomics, 2011, 75, 532-547.	2.4	11
60	Commensal Bifidobacterium Strains Enhance the Efficacy of Neo-Epitope Based Cancer Vaccines. Vaccines, 2021, 9, 1356.	4.4	10
61	Surface Interactome in Streptococcus pyogenes. Molecular and Cellular Proteomics, 2012, 11, M111.015206.	3.8	9
62	TCTN2: a novel tumor marker with oncogenic properties. Oncotarget, 2017, 8, 95256-95269.	1.8	9
63	Outer Membrane Vesicles From The Gut Microbiome Contribute to Tumor Immunity by Eliciting Cross-Reactive T Cells. Frontiers in Oncology, 0, 12, .	2.8	8
64	Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis. JCI Insight, 2021, 6, .	5.0	7
65	Vaccinology: The art of putting together the right ingredients. Human Vaccines and Immunotherapeutics, 2016, 12, 1311-1317.	3.3	6
66	Multiple Stepwise Gene Knockout Using CRISPR/Cas9 in Escherichia coli. Bio-protocol, 2018, 8, e2688.	0.4	3
67	Bacterial vaccine discovery: From â€œbrute forceâ€•to high selectivity. Hum Vaccin, 2010, 6, 872-875.	2.4	1
68	Finding Protective Bacterial Antigens. , 2012, , 27-44.		1
69	In Vitro Transcription and Translation Coupled to Two-Dimensional Electrophoresis for Bacterial Proteome Analysis. , 0, , 183-210.		0